The Natural Flavanoid Senolytic Fisetin Mitigates Age-Related Changes in Frailty, Grip Strength, and the Skeletal Muscle Transcriptome in Old Mice
Authors: Murray Kevin , Rossman Matthew , Mahoney Sophia , Greenberg Nathan , Seals Douglas , Mankowski Robert , Clayton Zachary 
Published: May 2024

Background: Changes in skeletal muscle (SKM) with aging are characterized, in part, by reduced SKM strength and altered gene expression, both of which contribute to increased frailty. The age-related accumulation of excess senescent cells promotes the sequela of SKM aging and contributes to increased frailty. Thus, reducing senescent cell burden represents a promising therapeutic approach to improve SKM function and reduce frailty with aging. Senolytics are compounds that clear excess senescent cells. Currently available synthetic pharmacological senolytic agents harbor poor safety profiles and have low translational application; thus, new approaches are required. Fisetin (FIS) is a natural flavonoid senolytic compound that may fit this need. However, whether FIS supplementation lowers frailty and mitigates the sequela of SKM aging remains unknown. Hypothesis: FIS supplementation in old mice will ameliorate age-related changes in frailty, SKM strength, and senescence-related gene expression in SKM. Methods: We assessed frailty (via a validated frailty index) and SKM strength (via forelimb grip strength) in old (27 mo) male and female C57BL6/N mice following intermittent oral supplementation of either FIS (OFIS, N=39/19 female; 100 mg/kg/day in vehicle [10% EtOH; 30% PEG400; 60% Phosal 50 PG]; 1 week on — 2 weeks off — 1 week on) or vehicle (OC, N=31/13 female). mRNA expression was assessed in isolated quadriceps SKM via bulk RNA sequencing (N=10/group; 5 female). Results were also compared to a young (6 mo) control reference group (YC, N=10; 5 female). Sex differences were not observed, therefore, data were combined for male and female mice. Data are mean ± SEM. Results: Frailty was higher (OC: 0.27 ± 0.01 vs. YC: 0.01 ± 0.004; p<0.05) and grip strength was lower (OC: 2.9g ± 0.01 vs. YC: 4.4g ± 0.02; p<0.05) in old relative to young mice. Pathways associated with cellular senescence were enriched in SKM of OC compared to YC. Some of the most overly expressed genes with aging were related to cellular senescence (e.g., Ankrd1, Gadd45a, Cdkn1a). FIS supplementation reduced the age-related increase in frailty by ~15% (OFIS, 0.23 ± 0.01; p<0.05 vs. OC) and diminished the age-related decline in grip strength by ~30% (OFIS, 3.3g ± 0.1; p<0.05 vs. OC). FIS altered the overall SKM transcriptome in old mice characterized by (1) a less distinct aging phenotype vs. YC analyzed via principal component analysis; and (2) less or no longer enriched cellular senescence-related pathways. A total of six genes were different in OFIS vs. OC (p<0.05; Log 2-fold change ± 0.5). Notably, Adh1 (alcohol dehydrogenase 1; positively associated with longevity) was higher and Ddit4 (DNA damage inducible transcript 4; positively related to DNA damage-induced senescence) was lower. Conclusions: Intermittent oral supplementation with FIS may be an effective therapeutic strategy to treat the sequela of SKM aging and frailty. However, to elicit greater changes in frailty and SKM strength with aging, a stronger or longer FIS dosing paradigm may be required. F32 HL167552; K01 DK115524; AHA 23CDA1056582; F31 HL165885; F31 HL164004; R01 AG055822-S1; K99 HL159241. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.